1Donowitz GR. Third - generation cephalosporins Infect Dis Clin North Am. 1989,3;595.
2Natalic CKein. Third - Generation Cephalosporins Med Clin North Am. 1995,79:705.
3Klein Nc, Cunha BA. The practical selection and use of cephalosporins Advances in Therpy. 1995,12:83.
4Fekety FR. Safety of Parenteral third generation cephalosporina Am J Med. 1990,88:38.
5Klastersky J. Cefoperazone in the theatment of injections in cancer patients Am J med. 1998,85:9.
6Schaad UB, Wedgewood - Krucko J, Tschaeppleler H. Reversible ceftriaxone - associated biliary pseudolithiasis in children. Lancet 1988. 2: 1411.
7Sattle FR, Weitkamp MR, Ballerd JO. Potential for bleeding with β-lactam antibiotics.Ann interm Med. 1986,105:924.
8Schaad UB, suterS, Gianella- Borradori A. et al. A comparison of ceftriaxone and ceftriaoxime for the treatment of bacterialmeningitis in children N Engl J Med. 1990, 322:141.
9Thomsberry C. Review of in vitro activity of third - generation cephalosporins and other new β- lactam antibiotics against clinically important bacteria. Am J Med. 1995.79:14.
10YukJH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokkinetics of ceftriaxone. Clin Pharmacokin. 1989, 17: 223.
